Peptic Ulcer Drugs Market to Hit USD 5.13 Billion by 2027 Backed by Rising Healthcare Expenditure in Europe


Peptic Ulcer Drugs Market: RedHill Biopharma Announces the U.S. Commercial Launch of Talicia to Strengthen its Product Portfolio

.

The global “Peptic Ulcer Drugs” Market is projected to showcase exponential growth by reaching USD 5.13 billion by 2027 while exhibiting a CAGR of 2.4% between 2020 and 2027. This is attributable to the increasing prevalence of peptic ulcer disease and the growing demand for effective peptic ulcer drugs across the globe. Fortune Business Insights, in its latest report, titled, “Peptic Ulcer Drugs Market Size, Share COVID-19 Imapct Analysis, By Drugs Type (Proton Pump Inhibitor (PPI), H2 Antagonists, Antibiotics, and Others), By Ulcer Type (Gastric Ulcer and Duodenal Ulcer), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2020-2027.”, mentions that the market was valued at USD 4.25 billion in 2019 and is likely to gain momentum in the forthcoming years.

Request a Sample Copy of the Research Report:

https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/peptic-ulcer-drugs-market-103483

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations travel bans and quarantines restaurants closed all indoor events restricted over forty countries state of emergency declared massive slowing of the IT Spending market volatility falling business confidence, growing panic among the population, and uncertainty about future.

Out research methodology is robust and includes data triangulation based on bottom-up and top-down approaches. We validated the approximate market number with the help of primary research. Secondary research was conducted to find out detailed information about mergers acquisitions, collaborations, joint ventures, and agreements. At the same time, we have derived significant information about the market dynamics associated with growth drivers, trends, and obstacles.

What does the Report Include?

The market report includes quantitative and qualitative analysis of several factors such as the key drivers and restraints that will impact growth. Additionally, the report provides insights into the regional analysis that covers different regions, which are contributing to the growth of the market. It includes the competitive landscape that involves leading companies and the adoption of strategies by them to introduce new products, announce partnerships, and collaboration that will contribute to the growth of the market between 2020 and 2027. Moreover, the research analyst has adopted several research methodologies such as PESTEL and SWOT analysis to extract information about the current trends and industry developments that will drive the market growth in the forthcoming years.

An Overview of the Impact of COVID-19 on this Market :

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of corona virus outbreak across industries to help you prepare for the future.

For more information visit : https://www.fortunebusinessinsights.com/peptic-ulcer-drugs-market-103483

List of the Companies Operating in the Global Market

  • AstraZeneca (Cambridge, United Kingdom)
  • Novartis AG (Basel, Switzerland)
  • Pfizer Inc. (New York, United States)
  • GlaxoSmithKline plc. (Brentford, United Kingdom)
  • Takeda Pharmaceutical Company Limited. (Tokyo, Japan)
  • Mylan Pharmaceuticals Inc. (Canonsburg, Pennsylvania, United States)
  • Abbott (Illinois, United States)
  • ZydusCadila (Gujrat, India)
  • Other Players

Soaring Demand for Peptic Ulcer Drugs In spite of COVID-19 Pandemic

The COVID-19 pandemic has led to the halt of several industrial processes causing unprecedented economic loss. However, pharmaceutical companies are thriving in these difficult times owing to the increasing demand for medication drugs across the globe. Likewise, the demand for these ulcer drugs is experiencing considerable growth as major pharmaceutical companies are increasing their focus on RD activities to develop new drugs and cater to the demand for the OTC drugs across several stores. The market is, therefore, expected to showcase positive growth during the forecast period.

Quick Buy -  Peptic Ulcer Drugs Market Research Report:

https://www.fortunebusinessinsights.com/checkout-page/103483

DRIVING FACTORS

Increasing Prevalence of Peptic Ulcer Disease to Spur Demand

According to the Harvard Health Publishing, every year peptic ulcers affect more than 4 million people in the U.S. Additionally, it occurs irrespective of the age bracket, and is estimated that 1 in 10 individuals are likely to develop this disease at some point of their life. The increasing prevalence of peptic ulcer disease is driving the demand for effective peptic ulcer drugs across the globe. Furthermore, the growing geriatric population is expected to contribute to the growth of the global peptic ulcer drugs market in the forthcoming years.

REGIONAL ANALYSIS

Increasing Incidence of Disease in North America to Aid Growth

Among all the regions, North America was worth USD 1.76 billion in 2019 and is expected to hold the highestmarket share in the forthcoming years. This is attributable to the increasing incidence of peptic ulcers in the U.S. that drives the demand for peptic ulcer drugs in the region. On the other hand, Europe is anticipated to hold the second position during the forecast period. This is ascribable to factors such as the rising healthcare expenditure in countries such as the U.K., France, and Germany between 2020 and 2027.

COMPETITIVE LANDSCAPE:

Product Launches by Major Companies to Strengthen TheirPortfolios

The global peptic ulcer drugs market is mainly dominated by major companies such as Pfizer, Inc., and AstraZeneca. These companies are actively investing in RD activities to introduce new products and maintain their dominance in the global marketplace. Furthermore, the other key players are adopting strategies such as collaboration, partnership, and merger and acquisition to maintain their presencein the fiercely competitive market during the forecast period.

Industry Development:

  • March 2020: RedHill Biopharma announced the commercial launch in the U.S. of Talicia, a capsule to treat H.pylori infection in patients. The announcement by the leading pharma company is expected to strengthen its market position in the near future.

Have Any Query? Ask Our Experts:

https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/peptic-ulcer-drugs-market-103483